Birchview Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Birchview Capital’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10,000	Closed	-$373K	–	66
2021 Q2	$373K	Hold	10,000	–	–	0.22%	51
2021 Q1	$256K	Hold	10,000	–	–	0.15%	50
2020 Q4	$220K	Hold	10,000	–	–	0.13%	46
2020 Q3	$180K	Hold	10,000	–	–	0.12%	48
2020 Q2	$254K	Hold	10,000	–	–	0.15%	49
2020 Q1	$184K	Hold	10,000	–	–	0.16%	42
2019 Q4	$220K	Sell	10,000 -30,000	-75%	-$604K	0.16%	46
2019 Q3	$574K	Sell	40,000 -5,000	-11%	-$71.5K	0.38%	25
2019 Q2	$709K	Hold	45,000	–	–	0.43%	24
2019 Q1	$659K	Hold	45,000	–	–	0.41%	23
2018 Q4	$481K	Hold	45,000	–	–	0.46%	27
2018 Q3	$687K	Hold	45,000	–	–	0.44%	24
2018 Q2	$551K	Hold	45,000	–	–	0.37%	29
2018 Q1	$430K	Hold	45,000	–	–	0.28%	32
2017 Q4	$406K	Hold	45,000	–	–	0.24%	27
2017 Q3	$259K	Buy	45,000 +25,000	+125%	+$91K	0.13%	31
2017 Q2	$63K	Buy	+20,000	New	+$63.2K	0.03%	40

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Birchview Capital's DRNA Position: Q3 2021 in Review

Birchview Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2021, closing a stake of 10,000 shares — an estimated $373K sold.

Birchview Capital first reported a position in DRNA in Q2 2017 and held it in 17 quarters. The position peaked at $709K in Q2 2019. 173 funds tracked by Wall St. Rank hold DRNA as of Q3 2021.

Birchview Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Birchview Capital sold 10,000 Dicerna Pharmaceuticals, Inc. shares in Q3 2021, an estimated $373K.
Birchview Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2017 and held it in 17 quarters.
Birchview Capital's Dicerna Pharmaceuticals, Inc. position peaked at $709K in Q2 2019.
173 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2021.

Based on Birchview Capital's 13F filing for Q3 2021, filed 12 Nov 2021.